Fruzaqla / Fruquin (Fruquintinib) 5mg

0.00$

+ Free Shipping
Key Info Details
Brand Names Fruzaqla / Fruquin
Generic Name Fruquintinib
Generic Brand Name Fruquin
Strength 5 mg
Form Capsules
Pack Size 21 Capsules
Manufacturer Everest Pharmaceuticals Ltd., Bangladesh
Therapeutic Class Targeted Therapy / VEGFR Inhibitor
Indication Metastatic Colorectal Cancer (mCRC)
Availability In Stock — Worldwide Delivery
Guaranteed Safe Checkout

Fruzaqla / Fruquin (Fruquintinib) 5mg

Fruquin (Fruquintinib INN) 5mg, manufactured by Everest Pharmaceuticals Ltd., is an advanced targeted therapy indicated for the treatment of metastatic colorectal cancer (mCRC). Fruquintinib is a potent and highly selective VEGFR inhibitor designed to block tumor angiogenesis, thereby slowing tumor growth and disease progression.

It is recommended for patients who have previously received standard chemotherapy, including fluoropyrimidine, oxaliplatin, or irinotecan-based regimens.

How Fruquintinib Works

Fruquintinib selectively inhibits:

  • VEGFR-1

  • VEGFR-2

  • VEGFR-3

These receptors are essential for developing blood vessels that supply tumors. By blocking them, Fruquin reduces blood flow to cancer cells, limiting their ability to grow and survive.

Indications

Fruquin (Fruquintinib INN) is used for:

  • Adult patients with metastatic colorectal cancer (mCRC)

  • Cases where disease has progressed despite prior chemotherapy or targeted therapy

It provides an important treatment option when other therapies are no longer effective.

Dosage & Administration

  • Standard recommended dose: 5 mg once daily

  • Treatment schedule: 3 weeks on, 1 week off (3/1 cycle)

  • Capsules should be swallowed whole with water

  • Can be taken with or without food

Dose may be adjusted depending on patient tolerance and side effects.

Possible Side Effects

Common side effects include:

  • Fatigue

  • Hypertension (high blood pressure)

  • Hand-foot skin reaction

  • Diarrhea

  • Mouth sores

  • Decreased appetite

  • Proteinuria

Serious but uncommon:

  • Bleeding

  • Blood clots

  • Gastrointestinal perforation

Patients should report any severe symptoms immediately.

Pregnancy & Lactation

  • Not recommended during pregnancy

  • Use effective contraception during treatment

  • Avoid breastfeeding during therapy and for a safe period afterward

Precautions & Monitoring

  • Monitor blood pressure regularly

  • Liver and kidney function tests are required

  • Caution in patients with bleeding risks

  • Avoid strong CYP450 enzyme inhibitors unless approved by a doctor

Storage

  • Store below 25°C

  • Keep away from light and moisture

  • Store out of reach of children

Let's chat